Clinical trials: Lymphoma
Leukemia
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Giving intensity modulated radiation therapy (IMRT) and chemotherapy, such as etoposide and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00576979
- Testing
- cyclophosphamide, etoposide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02706405
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lymphoid Leukemia, Non-Hodgkin's Lymphoma
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04155840
- Testing
- Copanlisib, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Moderate or Severe Submental Fullness
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study
Evaluation of the safety, tolerability and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01032889
- Testing
- Deoxycholic acid injection
- Where
- 10 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or…
- Trial name
- NCT00866749
- Testing
- Daunorubicin, Vincristine, PEG-asparaginase
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL).
- Conditions
- Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00244855
- Testing
- pharmacological study, rituximab, dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell…
- Conditions
- Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
- Trial name
- NCT02309515
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01088048
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Gilead Sciences
Non-Hodgkin Lymphoma
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab…
- Trial name
- NCT05296525
- Testing
- GDA-201
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gamida Cell ltd
Acute Lymphoblastic Leukemia, Pediatric
Vaccine Immune Recovery After Leukemia
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia…
- Trial name
- VIRAL (NCT05622682)
- Testing
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Where
- 6 sites in United States
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
Relapsed Lymphomas, Refractory Lymphomas
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
- Trial name
- NCT00785798
- Testing
- Vorinostat, Pegylated Liposomal Doxorubicin (PLD), Doxil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT02458014
- Testing
- Blinatumomab, TKI
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of lenalidomide when given together with temsirolimus and to see how well it works in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that has come…
- Conditions
- AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma
- Trial name
- NCT01076543
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Temsirolimus
- Where
- 11 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.
- Trial name
- NCT03456726
- Testing
- Tazemetostat
- Where
- 28 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Eisai Co., Ltd.
Lymphoma,Non-Hodgkin
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have…
- Trial name
- CHRONOS-3 (NCT02367040)
- Testing
- Copanlisib (Aliqopa, BAY80-6946), Rituximab
- Where
- 187 sites in United States, Argentina and 35 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Diffuse Large B-cell Lymphoma
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
This phase II multi-institutional trial will explore the safety and efficacy of lenalidomide monotherapy given as maintenance therapy following salvage chemo-immunotherapy in patients with relapsed or refractory chemosensitive…
- Trial name
- RV-NHL-PI351 (NCT00799513)
- Testing
- Lenalidomide
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.